Pfizer
Search results
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Seagen is a global team of scientists, engineers, clinicians, advocates, and innovators with a shared commitment to transforming cancer care. We’re dedicated to creating a culture of integrity, collaboration, and diversity, where your drive will make a difference.
With Seagen’s proprietary, world-leading Antibody-Drug Conjugate (ADC) technology, together with the scale and strength of Pfizer's capabilities and expertise, we are poised to change the cancer treatment paradigm.
Dec 12, 2023 · Pfizer said on Tuesday it expects to close its $43 billion deal to buy cancer drugmaker Seagen later this week and plans to create a new oncology division that includes the acquisition early next...
Dec 14, 2023 · Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. “Cancer remains a leading cause of death, and one in three people in the U.S. will receive a cancer diagnosis in their lifetime.
Dec 14, 2023 · Dec 14, 2023 7:39am EST. Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer.
As a pioneer in antibody–drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. Our research team is highly motivated to build an innovative pipeline of transformative cancer therapeutics accelerated by best-in-class technology platforms.
Dec 14, 2023 · This press release contains forward-looking information about, among other topics, Pfizer’s acquisition of Seagen, Seagen’s ADC technology, Pfizer’s Oncology portfolio and Seagen’s ...
Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue. The pharmaceutical giant said Monday it will pay $229 in cash for each share of Seagen Inc. Pfizer then plans to let the biotech drug developer “continue innovating,” except with more resources ...
Mar 13, 2023 · Pfizer has agreed to acquire oncology-focused biotech Seagen for a total enterprise value of $43bn as the US pharmaceutical company refills its drugs pipeline amid a sharp fall in sales of its ...
